Which statement reflects disease-modifying therapy for multiple sclerosis?

Which statement reflects disease-modifying therapy for multiple sclerosis?

• A. Steroids for chronic management
• B. Plasmapheresis as the only therapy
• C. Interferons or glatiramer acetate
• D. Cryoprecipitate as maintenance therapy

Answer: (C)

Disease-modifying therapy for multiple sclerosis aims to alter the disease course by dampening the immune system’s attack on the central nervous system, which lowers relapse rates and slows disability progression. Interferon beta preparations and glatiramer acetate are classic examples because they modulate immune activity and reduce inflammatory processes in the CNS, leading to fewer clinical relapses and slower accumulation of MRI-detected lesions. These agents are used chronically to modify ongoing disease activity rather than to treat a single flare. Steroids are reserved for acute relapses to hasten recovery but don’t change the long-term trajectory. Plasmapheresis may be used in severe, steroid-refractory relapses in some cases, but it’s not a standard disease-modifying therapy. Cryoprecipitate has no role in MS treatment. Thus, interferons or glatiramer acetate best represent disease-modifying therapy.

Disease-modifying therapy for multiple sclerosis aims to alter the disease course by dampening the immune system’s attack on the central nervous system, which lowers relapse rates and slows disability progression. Interferon beta preparations and glatiramer acetate are classic examples because they modulate immune activity and reduce inflammatory processes in the CNS, leading to fewer clinical relapses and slower accumulation of MRI-detected lesions. These agents are used chronically to modify ongoing disease activity rather than to treat a single flare.

Steroids are reserved for acute relapses to hasten recovery but don’t change the long-term trajectory. Plasmapheresis may be used in severe, steroid-refractory relapses in some cases, but it’s not a standard disease-modifying therapy. Cryoprecipitate has no role in MS treatment. Thus, interferons or glatiramer acetate best represent disease-modifying therapy.